Skip to main content
argenx SE logo

argenx SE — Investor Relations & Filings

Ticker · 1AE ISIN · NL0010832176 LEI · 7245009C5FZE6G9ODQ71 BR Manufacturing
Open in API
Filings indexed 671 across all filing types
Latest filing 2025-12-15 Regulatory Filings
Country NL Netherlands
Listing BR 1AE

About argenx SE

https://www.argenx.com/?allow=1

argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, argenx SE, with the SEC. It primarily serves as a current report to disclose a press release issued on December 15, 2025, which is attached as Exhibit 99.1. The document states that the press release is incorporated by reference and is part of the company's registration statements. The text does not contain substantive financial data or detailed report content but rather announces the press release. The document length is short (2299 characters), and it functions as a notification of an external report rather than the report itself. According to the rules, such a document is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and for announcements of reports rather than the reports themselves.
2025-12-15 English
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
Regulatory Filings Classification · 95% confidence The document is a press release from argenx SE announcing the discontinuation of a Phase 3 clinical trial (UplighTED) due to futility results from an interim analysis. It provides details on the study design, the company's clinical development strategy, and forward-looking statements. As it is a corporate announcement regarding clinical trial outcomes and regulatory/market abuse disclosures, it falls under the category of a general regulatory filing or announcement.
2025-12-15 English
argenx Announces Results of Extraordinary General Meeting of Shareholders
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement detailing the results of an Extraordinary General Meeting (EGM) of shareholders, specifically reporting the voting outcome on a remuneration policy. This falls directly under the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2025-11-19 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It references an attached press release (Exhibit 99.1) dated November 18, 2025. The document is short (2114 characters) and primarily serves as a notification of the press release being filed, without containing substantive financial data or detailed report content. According to the rules, such documents that announce or attach other reports but do not contain the reports themselves should be classified as Regulatory Filings (RNS).
2025-11-18 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-14 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, argenx SE, with the SEC. It states that it includes a press release and an investor presentation as exhibits. The document itself is short (2125 characters) and primarily serves to report the issuance of these materials rather than containing detailed financial data or analysis. According to the 'Menu vs Meal' rule, such a document that announces or attaches other reports but does not contain substantive financial content should be classified as a Regulatory Filing (RNS).
2025-10-30 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.